Judith A Clements

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12046940/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression. Journal of Cellular Physiology, 2007, 213, 374-383.	4.1	957
2	Bioengineered 3D platform to explore cell–ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials, 2010, 31, 8494-8506.	11.4	533
3	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
4	Type II Transmembrane Serine Proteases. Journal of Biological Chemistry, 2001, 276, 857-860.	3.4	317
5	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	21.4	265
6	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
7	The Glandular Kallikrein Family of Enzymes: Tissue Specific Expression and Hormonal Regulation. Endocrine Reviews, 1989, 10, 393-419.	20.1	214
8	Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus. Endocrine Reviews, 2010, 31, 407-446.	20.1	214
9	Can tissue engineering concepts advance tumor biology research?. Trends in Biotechnology, 2010, 28, 125-133.	9.3	208
10	The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers. Critical Reviews in Clinical Laboratory Sciences, 2004, 41, 265-312.	6.1	198
11	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
12	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.3	153
13	Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. International Journal of Cancer, 2000, 88, 726-732.	5.1	125
14	Tissue-specific Expression Patterns and Fine Mapping of the Human Kallikrein (KLK) Locus on Proximal 19q13.4. Journal of Biological Chemistry, 2000, 275, 37397-37406.	3.4	125
15	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biological Chemistry, 2006, 387, 637-41.	2.5	123
16	Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs). Journal of Biological Chemistry, 2008, 283, 12293-12304.	3.4	122
17	Translating tissue engineering technology platforms into cancer research. Journal of Cellular and Molecular Medicine, 2009, 13, 1417-1427.	3.6	122
18	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118

JUDITH A CLEMENTS

#	Article	IF	CITATIONS
19	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 2520-2528.	2.9	100
20	Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clinical Cancer Research, 2003, 9, 1710-20.	7.0	95
21	Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate, 2011, 71, 1198-1209.	2.3	93
22	Localization of a New Prostate-specific Antigen-related Serine Protease Gene, KLK4 , Is Evidence for an Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3–13.4. Journal of Biological Chemistry, 1999, 274, 23210-23214.	3.4	90
23	Kallikrein-Related Peptidase 7 Promotes Multicellular Aggregation via the α5β1 Integrin Pathway and Paclitaxel Chemoresistance in Serous Epithelial Ovarian Carcinoma. Cancer Research, 2010, 70, 2624-2633.	0.9	82
24	Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment. PLoS ONE, 2012, 7, e40217.	2.5	75
25	Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 29-39.	6.1	71
26	Characterization of a novel gene,STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Molecular Carcinogenesis, 2001, 32, 44-53.	2.7	68
27	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	2.9	67
28	Identification and Characterization of KLK14, a Novel Kallikrein Serine Protease Gene Located on Human Chromosome 19q13.4 and Expressed in Prostate and Skeletal Muscle. Genomics, 2001, 73, 117-122.	2.9	56
29	A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocrine-Related Cancer, 2015, 22, 265-276.	3.1	56
30	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	9.4	56
31	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56
32	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	2.3	54
33	A bioengineered 3D ovarian cancer model for the assessment ofÂpeptidase–mediated enhancement of spheroid growth andÂintraperitoneal spread. Biomaterials, 2013, 34, 7389-7400.	11.4	53
34	Secretome and degradome profiling shows that Kallikreinâ€related peptidases 4, 5, 6, and 7 induce TGFβâ€1 signaling in ovarian cancer cells. Molecular Oncology, 2014, 8, 68-82.	4.6	51
35	Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate, 2007, 67, 348-360.	2.3	50
36	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50

JUDITH A CLEMENTS

#	Article	IF	CITATIONS
37	Paclitaxel Resistance and Multicellular Spheroid Formation Are Induced by Kallikrein-Related Peptidase 4 in Serous Ovarian Cancer Cells in an Ascites Mimicking Microenvironment. PLoS ONE, 2013, 8, e57056.	2.5	47
38	Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clinical and Experimental Metastasis, 2014, 31, 135-147.	3.3	47
39	Kallikrein 4 (KLK4), A New Member of the Human Kallikrein Gene Family Is Up-Regulated By Estrogen and Progesterone in the Human Endometrial Cancer Cell Line, KLE. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2323-2323.	3.6	42
40	TTYH2, a Human Homologue of the Drosophila melanogaster Gene tweety, Is Located on 17q24 and Upregulated in Renal Cell Carcinoma. Genomics, 2001, 77, 200-207.	2.9	40
41	A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clinical and Experimental Metastasis, 2014, 31, 435-446.	3.3	39
42	Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological Chemistry, 2008, 389, 653-668.	2.5	38
43	Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?. Biological Chemistry, 2006, 387, 697-705.	2.5	36
44	A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells. Rna, 2010, 16, 1156-1166.	3.5	36
45	The Molecular Biology of the Kallikreins and their Roles in Inflammation. , 1997, , 71-97.		34
46	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	3.5	34
47	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecologic Oncology, 2012, 127, 569-578.	1.4	33
48	The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biological Chemistry, 2006, 387, 707-14.	2.5	32
49	Kallikrein gene expression in human pituitary tissues. Clinical Endocrinology, 1996, 44, 223-231.	2.4	31
50	Epithelial-Mesenchymal Transition in Prostate Cancer and the Potential Role of Kallikrein Serine Proteases. Cells Tissues Organs, 2007, 185, 111-115.	2.3	30
51	Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU International, 2007, 99, 735-742.	2.5	30
52	Kallikrein gene expression in estrogen-induced pituitary tumors. Molecular and Cellular Endocrinology, 1988, 60, 225-232.	3.2	28
53	Genetic polymorphisms in the human tissue <i>kallikrein (KLK)</i> locus and their implication in various malignant and non-malignant diseases. Biological Chemistry, 2012, 393, 1365-1390.	2.5	24
54	Association Analysis of a Microsatellite Repeat in the TRIB1 Gene With Prostate Cancer Risk, Aggressiveness and Survival. Frontiers in Genetics, 2018, 9, 428.	2.3	24

JUDITH A CLEMENTS

#	Article	IF	CITATIONS
55	A novel transcript from the <i>KLKP1</i> gene is androgen regulated, downâ€regulated during prostate cancer progression and encodes the first nonâ€serine protease identified from the human kallikrein gene locus. Prostate, 2008, 68, 381-399.	2.3	23
56	Reflections on the tissue kallikrein and kallikrein-related peptidase family – from mice to men – what have we learnt in the last two decades?. Biological Chemistry, 2008, 389, 1447-1454.	2.5	22
57	Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology, Immunotherapy, 2012, 61, 169-179.	4.2	21
58	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	2.5	21
59	Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, <i>KLK5</i> and <i>KLK7</i> , and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biological Chemistry, 2008, 389, 99-109.	2.5	17
60	The <i>kallikrein 14</i> gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness. Biological Chemistry, 2012, 393, 403-412.	2.5	15
61	Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone. Cancers, 2018, 10, 438.	3.7	15
62	MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer. Clinical Chemistry, 2019, 65, 771-780.	3.2	15
63	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	2.8	14
64	Kallikrein 4 (KLK4), A New Member of the Human Kallikrein Gene Family Is Up-Regulated By Estrogen and Progesterone in the Human Endometrial Cancer Cell Line, KLE. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2323-2323.	3.6	13
65	A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness. Scientific Reports, 2017, 7, 16862.	3.3	12
66	Kallikrein-Related Peptidase 3(KLK3/PSA) Single Nucleotide Polymorphisms and Ovarian Cancer Survival. Twin Research and Human Genetics, 2011, 14, 323-327.	0.6	11
67	Selective Cleavage of Human Sex Hormone-Binding Globulin by Kallikrein-Related Peptidases and Effects on Androgen Action in LNCaP Prostate Cancer Cells. Endocrinology, 2012, 153, 3179-3189.	2.8	11
68	Hydrogel Microwell Arrays Allow the Assessment of Protease-Associated Enhancement of Cancer Cell Aggregation and Survival. Microarrays (Basel, Switzerland), 2013, 2, 208-227.	1.4	11
69	Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 2010, 391, 461-6.	2.5	8
70	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	6.4	7
71	Production and Characterization of Antipeptide Kallikrein 4 Antibodies: Use of Computer Modeling to Design Peptides Specific to Kallikrein 4. , 2003, 81, 241-254.		6
72	A computational analysis of the genetic and transcript diversity at the kallikrein locus. Biological Chemistry, 2016, 397, 1307-1313.	2.5	3

1

#	Article	IF	CITATIONS
73	Mining human cancer datasets for kallikrein expression in cancer: the â€~KLK-CANMAP' Shiny web tool. Biological Chemistry, 2018, 399, 983-995.	2.5	3

The Human Tissue Kallikrein and Kallikrein-related Peptidase Family. , 2013, , 2747-2756.